Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

JNJ

Johnson & Johnson

Dec 11 • 04:00PM ET

146.64

Dollar change -2.59
Percentage change -1.74	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: LLY PFE MRK AMGN BMY NVS ABBV GSK AZN MDT

| Held by: VTI VOO SPY IVV VTV XLV VIG VYM VHT IWD

Scroll to Statements

Index	DJIA, S&P 500	P/E	24.24	EPS (ttm)	6.05	Insider Own	0.12%	Shs Outstand	2.41B	Perf Week	-2.55%
Market Cap	353.05B	Forward P/E	13.85	EPS next Y	10.59	Insider Trans	-0.19%	Shs Float	2.40B	Perf Month	-5.42%
Income	14.68B	PEG	4.04	EPS next Q	2.02	Inst Own	72.73%	Short Float	0.77%	Perf Quarter	-10.93%
Sales	87.69B	P/S	4.03	EPS this Y	0.35%	Inst Trans	0.65%	Short Ratio	2.77	Perf Half Y	0.85%
Book/sh	29.14	P/B	5.03	EPS next Y	6.36%	ROA	8.58%	Short Interest	18.54M	Perf Year	-5.43%
Cash/sh	8.43	P/C	17.39	EPS next 5Y	6.00%	ROE	20.89%	52W Range	143.13 - 168.85	Perf YTD	-6.44%
Dividend Est.	4.64 (3.16%)	P/FCF	17.02	EPS past 5Y	-0.27%	ROI	14.47%	52W High	-13.15%	Beta	0.50
Dividend TTM	4.91 (3.35%)	Quick Ratio	0.79	Sales past 5Y	1.31%	Gross Margin	68.67%	52W Low	2.45%	ATR (14)	2.29
Dividend Ex-Date	Nov 26, 2024	Current Ratio	1.03	EPS Y/Y TTM	15.10%	Oper. Margin	24.60%	RSI (14)	25.06	Volatility	1.38% 1.47%
Employees	131900	Debt/Eq	0.51	Sales Y/Y TTM	-8.03%	Profit Margin	16.75%	Recom	2.17	Target Price	176.21
Option/Short	Yes / Yes	LT Debt/Eq	0.45	EPS Q/Q	-43.91%	Payout	84.93%	Rel Volume	2.01	Prev Close	149.23
Sales Surprise	1.35%	EPS Surprise	9.68%	Sales Q/Q	5.27%	Earnings	Oct 15 BMO	Avg Volume	6.69M	Price	146.64
SMA20	-3.95%	SMA50	-6.84%	SMA200	-5.67%	Trades		Volume	13,427,216	Change	-1.74%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Resumed	BofA Securities	Neutral	$166
Nov-15-24	Initiated	Wolfe Research	Outperform	$190
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral	$160 → $150
May-30-24	Resumed	Goldman	Neutral	$160
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy	$170
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$170 → $163
Dec-01-23	Upgrade	UBS	Neutral → Buy	$167 → $180
Oct-05-23	Initiated	RBC Capital Mkts	Outperform	$178
Sep-06-23	Initiated	HSBC Securities	Hold	$175
May-30-23	Resumed	Citigroup	Buy	$185
Mar-29-23	Initiated	UBS	Neutral	$164
Mar-01-23	Initiated	Guggenheim	Neutral	$161
Nov-18-22	Initiated	Credit Suisse	Neutral	$170
Oct-18-22	Initiated	Barclays	Equal Weight	$175
Oct-14-22	Reiterated	BofA Securities	Neutral	$185 → $178
Jun-22-22	Initiated	Daiwa Securities	Outperform
May-23-22	Resumed	SVB Leerink	Outperform	$200
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$173
Mar-16-22	Downgrade	Bernstein	Outperform → Mkt Perform	$180 → $183
Mar-02-22	Resumed	BofA Securities	Neutral	$185

Show Previous Ratings

Today 07:15AM	Johnson & Johnson reinstated with a Neutral at BofA (TipRanks)
05:41AM	ASH 2024: J&Js Tecvayli shows promise in transplant-eligible NDMM patient (Pharmaceutical Technology)
Dec-10-24 11:20PM	Why Is Johnson & Johnson (JNJ) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now? (Insider Monkey)
11:20PM	Why Is Johnson and#038; Johnson (JNJ) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now? (Insider Monkey)
05:45PM	Johnson & Johnson (JNJ) Stock Moves -0.25%: What You Should Know (Zacks)
11:27AM	Loading…
11:27AM	Retired Investor Living Off $160,000 In Dividends Shares Stock Portfolio 'We Live Quite Comfortably On Dividends' (Benzinga)
08:00AM	Johnson and Johnson to Host Investor Conference Call on Fourth-Quarter Results (Business Wire)
08:00AM	Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results (Business Wire)
06:00AM	Navigating Market Uncertainty: Intrinsic Value of Johnson & Johnson (GuruFocus.com)
Dec-09-24 07:30PM	CARVYKTI (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study (PR Newswire)
04:22PM	Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. (Investor's Business Daily)
08:00AM	Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson and Johnson highlights profound disease burden and unmet need for targeted treatment options (PR Newswire)
08:00AM	Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options (PR Newswire)
07:15AM	ASH24: Darzalex in smoldering myeloma, Mercks ADC data and Novos sickle cell drug (BioPharma Dive)
Dec-08-24 09:14PM	Apple Tops the List of Best-Managed Companies of 2024 (The Wall Street Journal)
07:30PM	Loading…
07:30PM	DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma (PR Newswire)
01:21PM	Advertising Firms Omnicom and Interpublic Nearing Merger That Would Reshape Industry (The Wall Street Journal)
12:33PM	TECVAYLI (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma (PR Newswire)
11:21AM	DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma (PR Newswire)
Dec-07-24 12:56PM	Is Johnson & Johnson (JNJ) Dominating A Billionaire Quants Investment Strategy Right Now? (Insider Monkey)
12:56PM	Is Johnson and#038; Johnson (JNJ) Dominating A Billionaire Quant's Investment Strategy Right Now? (Insider Monkey)
Dec-04-24 07:42PM	Analyst Report: Johnson & Johnson (Morningstar Research)
05:45PM	Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
08:05AM	Why Is Johnson & Johnson (JNJ) Among the Dividend Kings You Should Consider? (Insider Monkey)
03:00AM	The big rebrand: Why these 4 biopharmas changed their name this year (Pharma Voice)
Dec-03-24 09:00AM	You Buy Products From These Dual Dividend Aristocrat and Dividend King Stocks Every Day Why Not Earn Passive Income On Their Shares? (Benzinga)
06:19AM	J&Js sBLAs seek FDA approval of TREMFYA for paediatric conditions (Pharmaceutical Technology)
Dec-02-24 02:52PM	Why Dividend Aristocrats Like Walmart, ADP, and AbbVie Are Set to Outperform (Barrons.com)
01:29PM	Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know (Zacks)
08:00AM	Johnson and Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA (guselkumab) (PR Newswire)
08:00AM	Loading…
08:00AM	Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab) (PR Newswire)
07:46AM	Analyst Report: Johnson & Johnson (Morningstar Research)
07:25AM	Why Is Johnson & Johnson (JNJ) Among the Stocks Ray Dalios Bridgewater Is Crazy About? (Insider Monkey)
06:24AM	J&J appoints Shawn Millerick to lead vision care unit in the Americas (MedTech Dive)
Dec-01-24 05:52AM	3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later (Motley Fool)
04:55AM	These 3 Dividend-Focused Vanguard ETFs Are Up 14% to 31% in 2024. Here's the Best One to Buy Now. (Motley Fool)
Nov-28-24 07:45AM	2 Excellent Healthcare Stocks to Hold Through the Next Decade (Motley Fool)
Nov-26-24 12:00PM	How To Put $100 In Your Retirement Fund Each Month With Johnson & Johnson (Benzinga)
06:18AM	2 Very Healthy Dividend Stocks to Hold for Decades of Income (Motley Fool)
06:00AM	Navigating Market Uncertainty: Intrinsic Value of Johnson & Johnson (GuruFocus.com)
04:03AM	Sanofi joins J&J, Eli Lilly in proposing 340B rebate model (Healthcare Dive)
03:17AM	Is Johnson & Johnson (JNJ) the Best Dividend Aristocrat Stock To Buy Right Now? (Insider Monkey)
Nov-23-24 10:16AM	Hedge Funds Bet Big On Johnson & Johnson (JNJ): Top Healthcare Stock to Watch (Insider Monkey)
10:16AM	Hedge Funds Bet Big On Johnson and#038; Johnson (JNJ): Top Healthcare Stock to Watch (Insider Monkey)
07:20AM	3 Dividend Stocks That Are Screaming Buys in November (Motley Fool)
05:36AM	2 Unstoppable Dividend Stocks to Buy Now With $500 (Motley Fool)
04:02AM	2 Dow Jones Dividend Stocks With Yields Above 3% You Can Buy Now and Hold at Least a Decade (Motley Fool)
Nov-22-24 05:20PM	Sanofi Plans to Change Hospital Drug-Discount Program (The Wall Street Journal)
02:28PM	Layoffs in 2024: A List of Companies Cutting Jobs This Year (The Wall Street Journal)
12:25PM	J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis (Pharmaceutical Technology)
12:05PM	Medtronic acquires Fortimedix Surgical to boost surgical portfolio (Medical Device Network)
11:08AM	Health Canada issues NOC to J&Js CARVYKTI for multiple myeloma (Pharmaceutical Technology)
08:00AM	Johnson and Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor (PR Newswire)
Nov-21-24 04:00PM	Health Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy (PR Newswire)
Nov-19-24 09:02AM	Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting (PR Newswire)
09:00AM	Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know (Zacks)
06:24AM	J&J pill clears skin in two late-stage psoriasis studies (BioPharma Dive)
05:22AM	Johnson & Johnson reports topline outcomes from trial of icotrokinra for psoriasis (Clinical Trials Arena)
Nov-18-24 04:30PM	Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results (PR Newswire)
01:27PM	How Robert F. Kennedy Jr. could impact the healthcare sector as secretary of health (Yahoo Finance)
11:20AM	Johnson & Johnson appoints CIO to lead business technology strategy (CIO Dive)
05:28AM	Eli Lilly follows J&J in suing Biden administration over 340B rebates (Healthcare Dive)
12:43AM	Analyst Report: Johnson & Johnson (Morningstar Research)
Nov-15-24 09:02AM	Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program (Investopedia)
07:23AM	Johnson & Johnson MedTech announces partnership for soft tissue solutions (Medical Device Network)
06:51AM	J&Js nipocalimab shows promise in Phase II Sjögrens disease trial (Clinical Trials Arena)
Nov-14-24 11:30AM	Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report? (Zacks)
10:00AM	Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjgren's disease study (PR Newswire)
Nov-13-24 12:00PM	Why Johnson & Johnson, Invitation Homes And Extra Space Storage Are Winners For Passive Income (Benzinga)
11:58AM	J&J MedTech wins IDE for Ottava to greenlight trials for surgical robot (Medical Device Network)
03:33AM	J&J sues federal government for halting 340B rebate plan (Healthcare Dive)
03:28AM	Q3 2024 Legend Biotech Corp Earnings Call (Thomson Reuters StreetEvents)
02:00AM	TRex Bio raises $84M to compete in crowded immune drug field (BioPharma Dive)
Nov-12-24 03:04PM	J&J Sues U.S. Over Hospital Drug-Discounting Program (The Wall Street Journal)
06:40AM	J&Js Ottava surgical robot to begin clinical trial after FDA nod (MedTech Dive)
06:00AM	The Art of Valuation: Discovering Johnson & Johnson's Intrinsic Value (GuruFocus.com)
Nov-11-24 04:05PM	Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease (PR Newswire)
03:00AM	Spravato is just the beginning in a new wave of depression meds (Pharma Voice)
Nov-08-24 10:38AM	Why Johnson & Johnson (JNJ)s Legal Issues Could Wrap Up Quickly (Insider Monkey)
09:35AM	Analyst Report: Johnson & Johnson (Morningstar Research)
07:00AM	Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO / DARZALEX as subcutaneous monotherapy for high-risk smoldering multiple myeloma (PR Newswire)
05:27AM	Johnson & Johnson MedTechs VARIPULSE Platform receives FDA approval for AFib (Medical Device Network)
04:15AM	Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever (Motley Fool)
Nov-07-24 02:46PM	FDA Greenlights J&J's Varipulse Device for Safer Atrial Fibrillation Treatment (GuruFocus.com)
08:00AM	Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024 (PR Newswire)
06:35AM	J&J wins FDA approval for Varipulse PFA system (MedTech Dive)
Nov-05-24 09:00AM	Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Nov-04-24 06:35PM	Is Johnson & Johnson (JNJ) the Best Pharma Stock to Buy Right Now? (Insider Monkey)
03:11PM	Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare (GlobeNewswire)
Nov-01-24 08:35AM	Johnson & Johnson MedTech concludes enrolment for OMNY-AF trial pilot phase (Medical Device Network)
07:47AM	J&J Medtech CIO Larry Jones resigns (MedTech Dive)
Oct-31-24 04:00AM	Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions (Pharmaceutical Technology)
Oct-29-24 09:19AM	J&J and Lilly both unveil IL-23 inhibitor efficacy in Crohns disease (Clinical Trials Arena)
09:19AM	J&J and Lilly both boast IL-23 inhibitor efficacy in Crohns disease (Clinical Trials Arena)
08:00AM	Invest with Confidence: Intrinsic Value Unveiled of Johnson & Johnson (GuruFocus.com)
06:32AM	J&J to seek FDA approval after small-bore Impella heart pump hits trial goal (MedTech Dive)
Oct-28-24 12:33PM	J&Js $8.2 Billion Talc Settlement Faces January Court Test (Bloomberg)
12:09PM	AbbVie to Acquire Aliada Therapeutics for $1.4 Billion (The Wall Street Journal)
11:32AM	Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease (Benzinga)
07:30AM	TREMFYA (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease (PR Newswire)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hait William	Former Officer	Dec 04 '24	Proposed Sale	149.90	25,742	3,858,598		Dec 04 01:25 PM
Decker Robert J	VP Corporate Controller	Aug 30 '24	Option Exercise	100.06	5,635	563,838	24,608	Sep 03 04:48 PM
Decker Robert J	VP Corporate Controller	Aug 30 '24	Sale	165.06	5,635	930,113	18,973	Sep 03 04:48 PM
Decker Robert J	Officer	Aug 30 '24	Proposed Sale	165.06	5,635	930,113		Aug 30 03:51 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Jul 08 '24	Option Exercise	0.00	9,809	0	24,852	Jul 09 05:48 PM
REED JOHN C	EVP, Innovative Medicine, R&D	May 01 '24	Option Exercise	0.00	22,255	0	22,561	May 03 04:31 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Mar 13 '24	Sale	162.16	8,891	1,441,765	15,043	Mar 13 04:36 PM
JOHNSON & JOHNSON	10% Owner	Feb 29 '24	Option Exercise	0.72	3,855	2,792	4,103,430	Mar 06 03:42 PM
JOHNSON & JOHNSON	10% Owner	Feb 16 '24	Sale	25.81	3,725	96,142	4,099,575	Mar 06 03:42 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 13 '24	Option Exercise	0.00	651	0	82,599	Feb 15 04:53 PM
Wolk Joseph J	Exec VP, CFO	Feb 13 '24	Option Exercise	0.00	1,780	0	69,663	Feb 15 04:53 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 13 '24	Option Exercise	0.00	1,302	0	155,517	Feb 15 04:53 PM
Swanson James D.	EVP, CIO	Feb 13 '24	Option Exercise	0.00	447	0	14,765	Feb 15 04:53 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 13 '24	Option Exercise	0.00	499	0	13,290	Feb 15 04:53 PM
Fasolo Peter	Exec VP, Chief HR Officer	Feb 13 '24	Option Exercise	0.00	925	0	112,550	Feb 15 04:53 PM
Hait William	See Remarks	Feb 13 '24	Option Exercise	0.00	834	0	39,074	Feb 15 04:53 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 13 '24	Option Exercise	0.00	3,470	0	364,809	Feb 15 04:53 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 13 '24	Option Exercise	0.00	408	0	24,143	Feb 15 04:53 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 13 '24	Option Exercise	0.00	651	0	8,576	Feb 15 04:53 PM
Decker Robert J	VP Corporate Controller	Feb 13 '24	Option Exercise	0.00	313	0	19,059	Feb 15 04:53 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 12 '24	Option Exercise	0.00	4,701	0	25,081	Feb 14 06:36 PM
Hait William	See Remarks	Feb 12 '24	Option Exercise	0.00	8,932	0	42,316	Feb 14 06:36 PM
Wolk Joseph J	Exec VP, CFO	Feb 12 '24	Option Exercise	0.00	25,835	0	78,699	Feb 14 06:36 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 12 '24	Option Exercise	0.00	2,859	0	8,959	Feb 14 06:36 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 12 '24	Option Exercise	0.00	26,202	0	167,618	Feb 14 06:36 PM
Fasolo Peter	Exec VP, Chief HR Officer	Feb 12 '24	Option Exercise	0.00	14,960	0	118,644	Feb 14 06:36 PM
Swanson James D.	EVP, CIO	Feb 12 '24	Option Exercise	0.00	5,456	0	16,013	Feb 14 06:36 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 12 '24	Option Exercise	0.00	36,618	0	377,239	Feb 14 06:36 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 12 '24	Option Exercise	0.00	5,736	0	15,678	Feb 14 06:36 PM
Decker Robert J	VP Corporate Controller	Feb 12 '24	Option Exercise	0.00	1,912	0	19,269	Feb 14 06:36 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 12 '24	Option Exercise	0.00	13,813	0	89,014	Feb 14 06:36 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 09 '24	Option Exercise	90.44	130,969	11,844,836	439,283	Feb 13 05:18 PM
Taubert Jennifer L	EVP, WW Chair, Pharmaceuticals	Feb 09 '24	Option Exercise	90.44	59,397	5,371,865	200,813	Feb 12 07:25 PM
Taubert Jennifer L	EVP, WW Chair, Pharmaceuticals	Feb 08 '24	Option Exercise	0.00	3,739	0	143,329	Feb 12 07:25 PM
Taubert Jennifer L	EVP, WW Chair, Pharmaceuticals	Feb 09 '24	Sale	156.27	59,397	9,281,969	141,416	Feb 12 07:25 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 08 '24	Option Exercise	0.00	5,225	0	310,583	Feb 12 07:25 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 08 '24	Option Exercise	0.00	1,971	0	67,905	Feb 12 07:25 PM
Wolk Joseph J	Exec VP, CFO	Feb 08 '24	Option Exercise	0.00	3,686	0	53,911	Feb 12 07:25 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 08 '24	Option Exercise	0.00	979	0	6,463	Feb 12 07:24 PM
Swanson James D.	See Remarks	Feb 08 '24	Option Exercise	0.00	1,868	0	11,111	Feb 12 07:24 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 08 '24	Option Exercise	0.00	1,964	0	10,943	Feb 12 07:24 PM
Fasolo Peter	Exec VP, Chief HR Officer	Feb 08 '24	Option Exercise	0.00	2,135	0	104,465	Feb 12 07:24 PM
Hait William	See Remarks	Feb 08 '24	Option Exercise	0.00	3,059	0	34,497	Feb 12 07:24 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 08 '24	Option Exercise	0.00	1,880	0	21,083	Feb 12 07:24 PM
Decker Robert J	VP Corporate Controller	Feb 08 '24	Option Exercise	0.00	655	0	17,572	Feb 12 07:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JNJ

Johnson & Johnson

Upgrade your FINVIZ experience